Benzinga | Sep 22, 2021 06:58AM EDT

Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $180

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $174 to $180.